We detect Systemic Chronic Inflammation to help people change the course of their Aging Process.

Our Science

iuve is based on paradigm shifting research how SYSTEMIC CHRONIC INFLAMMATION (SCI) predicts the onset of multiple chronic diseases, such as cardiovascular disease, cancer, neurodegenerative disorders, and many others. In simple words, SCI defines the rate of aging of an individual.
The company’s proprietary innovation is backed by the Stanford 1000 Immunomes Project, the largest study of immunity and aging to date.

Our Science

iuve is based on paradigm shifting research how SYSTEMIC CHRONIC INFLAMMATION (SCI) predicts the onset of multiple chronic diseases, such as cardiovascular disease, cancer, neurodegenerative disorders, and many others. In simple words, SCI defines the rate of aging of an individual.
The company’s proprietary innovation is backed by the Stanford 1000 Immunomes Project, the largest study of immunity and aging to date.

Multidimensional Data
Deep Neural Network (A.I.)
Systemic Chronic Inflammation metric

What is Systemic Chronic Inflammation?

When we hear the word “Inflammation”, we think of a red, warm, swollen toenail. These are indeed clinical signs of acute inflammation, which is the body’s response to an infection or trauma.

Systemic Chronic Inflammation (SCI) is very different from acute inflammation since it is triggered by a) debris from improper cellular metabolism and b) the exposure to environmental pollutants, processed foods, pesticides, chronic stress, etc., known as the “EXPOSOME”.

While acute inflammation is beneficial and should resolve in less than a week, SCI accumulates with time in some individuals causing collateral damage to tissues and organs and augmenting the risk of most, if not all, age-associated diseases.

Evaluation of acute inflammation can be easily done by lab tests, however to date there were no standard tests in the market for SCI.

Scientists at the Stanford School of Medicine developed the first test for SCI, which can inform patients and doctors about the SCI of a subject. This new ‘metric’ for general health, which predicts a variety of chronic illnesses, is backed by the largest database for human immunity and aging, and cutting-edge artificial intelligence algorithms.

 Acute InflammationSystemic Chronic Inflammation
triggerinfection, traumacellular debris, environmental insults (EXPOSOME)
durationshort termpersistent, non-resolving
magnitudehigh gradelow grade
outcome(s)healing, trigger removal, tissue_repaircollateral damage, diseases of aging
age-relatednoyes
markersIL-6, TNF-α, IL-1β, CRPno canonical standard blood markers

Our Leadership

Founder and Chief Scientific Officer

David Furman, PhD

Director, Stanford 1000 Immunomes Project
Principal Investigator, National Scientific Research Council, Argentina

Artificial Intelligence in Biomarker Discovery

Scientific Co-founder

Mark M. Davis, PhD

Director, Stanford Institute for Immunity, Transplantation and Infection
Professor of Immunology, Stanford School of Medicine

Molecular Immunology and Systems Immunology

Scientific Advisor

Stanley Rockson, MD

Professor of Lymphatic Research and Medicine, Stanford School of Medicine
Preventive Cardiovascular Aging

Scientific Co-founder

Mark M. Davis, PhD

Director, Stanford Institute for Immunity, Transplantation and Infection
Professor of Immunology, Stanford School of Medicine

Molecular Immunology and Systems Immunology

Founder and Chief Scientific Officer

David Furman, PhD

Director, Stanford 1000 Immunomes Project
Principal Investigator, National Scientific Research Council, Argentina

Artificial Intelligence in Biomarker Discovery

Executive Chairman

Wolfgang Daum, PhD

Managing Partner of The Carlyle Group
Angel investor with Keiretsu Forum in Palo Alto, CA
Wolfgang is a serial entrepreneur who has helped build and successfully exited from many life science companies in the areas of medical diagnostics and medical devices for neurological disease, cardiovascular disease and oncology.

Executive VP, Sales & Marketing

Krinx Kong, BBA

Krinx received his BBA in Marketing from the McCombs School of Business at the University of Texas, Austin.
His career began during his Senior year where he was hired by Merck & Co. For the following 22 years, he’s been delivering results with leadership roles in commercial healthcare sales, marketing and business development, primarily in the areas of cardiovascular disease, oncology and clinical wellness.
His broad range of experience in the healthcare sector from early stage start-ups to fortune 500 companies in the pharma, hospital and laboratory diagnostic space sets him apart.

CFO

Anna Lau, MBA, CPA (inactive, FL)

Angel investor with Portfolia and Berkeley Angel Network
UNC-Chapel Hill MBA in Strategy & Marketing, BS Accounting, BS Finance, former CPA
Anna’s experience in accounting, finance, sales and HR spans from Fortune 100 multinational companies to health tech startups.

Partnering

Our mission is to change the global burden of chronic diseases by helping people to diagnose their inflammation and change the course of their health. Hence, the applications of our SCI test are multiple and include

  • pharma (companion diagnostics – drug repositioning)

  • wellness clinics

  • health and life insurance companies

  • preventative medicine

  • direct to consumer

  • academia/research

As scientists, we understand the value of collaborative work and we thrive to partner.

Contact Us